Common Contracts
4 similar Underwriting Agreement contracts by Calithera Biosciences, Inc., Cue Biopharma, Inc., Goldman Sachs BDC, Inc., Ocugen, Inc.
CUE BIOPHARMA, INC. (a Delaware corporation) 11,564,401 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 12,435,599 Shares of Common Stock Warrants to Purchase Up to 6,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2024 • Cue Biopharma, Inc. • Pharmaceutical preparations • New York
30,434,783 Shares OCUGEN, INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE Underwriting AgreementUnderwriting Agreement • August 1st, 2024 • Ocugen, Inc. • Biological products, (no disgnostic substances) • New York
GOLDMAN SACHS BDC, INC. (a Delaware corporation) $400,000,000 6.375% Notes due 2027 UNDERWRITING AGREEMENT Dated: March 6, 2024Underwriting Agreement • March 11th, 2024 • Goldman Sachs BDC, Inc. • New York
Goldman Sachs BDC, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA is acting as representative (in such capacity, the “Representative”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of $400,000,000 aggregate principal amount of 6.375% Notes due 2027 (the “Securities”).
Calithera Biosciences, Inc. 12,500,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • June 19th, 2019 • Calithera Biosciences, Inc. • Pharmaceutical preparations • New York
Calithera Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 12,500,000 shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,875,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriter, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms
